Dupilumab for the treatment of moderate and severe atopic dermatitis: real-life experience.
Postepy Dermatol Alergol
; 40(6): 747-752, 2023 Dec.
Article
em En
| MEDLINE
| ID: mdl-38282886
ABSTRACT
Introduction:
Atopic dermatitis is a relapsing, chronic, inflammatory dermatosis. So far, treatment options for more severe forms of the disease have been limited. The prospect has changed with the advent of biological drug registrations. Dupilumab is a monoclonal antibody targeting the a subunit of the IL-4 receptor and is responsible for blocking the signalling of interleukin (IL) 4 (IL-4) and IL-13. Clinical trials conducted for over 10 years have confirmed the efficacy and safety of dupilumab's treatment for atopic dermatitis.Aim:
Evaluating the efficacy of dupilumab treatment in patients with moderate and severe atopic dermatitis in real life. Material andmethods:
We retrospectively evaluated medical records of patients treated with dupilumab for atopic dermatitis at the Department of Dermatology, Venereology and Allergology in Gdansk.Results:
Ten patients in total were studied. They received dupilumab with standard dosing. The mean percentage reduction in SCORAD score was 52.16% in 8 weeks. Dupilumab was generally well tolerated and did not cause serious side effects. The most common adverse event was conjunctivitis.Conclusions:
Dupilumab is an effective disease-modifying drug for patients with moderate to severe atopic dermatitis. The effects of treatment in real life are consistent with those demonstrated in clinical trials.
Texto completo:
1
Bases de dados:
MEDLINE
Idioma:
En
Revista:
Postepy Dermatol Alergol
Ano de publicação:
2023
Tipo de documento:
Article
País de afiliação:
Polônia